Our study published in European Radiology demonstrated that combining PSA density, PI‑RADS and the AI score significantly improves diagnostic accuracy and reduces unnecessary biopsies. The takeaway is clear: clinicians should not have to assemble this integrated approach themselves.
The Integrated Risk Score was created for that reason. It gives a single patient‑level estimate of the likelihood of clinically significant prostate cancer, expressed on a 10–100 scale with clear categories: low, intermediate, high, very high risk.
It looks simple, but it represents a shift from separate indicators to a unified assessment grounded in published evidence. A single output that brings the key signals together.
📽️ Watch a short video to learn more: https://lnkd.in/djziAVUy
Study: Sushentsev, N., Arya, Z., Budd, J. et al. AI decision support for increasing prostate biopsy efficiency: a retrospective multicentre, multiscanner study. Eur Radiol 36, 5719–5727 (2026).